Univest
Univest
  • Markets

Healthcare Stocks Today: Apollo Hospitals Rises 4.3% to a 52-Week High, Max Healthcare Gains 2.9% After Macquarie Upgrade, Aster Adds 3.1% and Molbio Slips

  • November 20, 2026
  • Posted by: Harsh Piplani
  • Category: News
No Comments
Healthcare Stocks Today: Apollo Hospitals Rises 4.3% to a 52-Week High, Max Healthcare Gains 2.9% After Macquarie Upgrade, Aster Adds 3.1% and Molbio Slips

Apollo Rs 9,109 (+4.25%), Max Rs 1,071.10 (+2.93%), Aster Rs 762.10 (+3.08%), Molbio Rs 1,512.80 (-0.89%) at 11:46 IST. Macquarie targets: Apollo 10,500, Max 1,450. NSE, 20 Nov 2026.

Quick Answer

Hospital shares are rising on 20 November after Macquarie upgraded Apollo Hospitals and Max Healthcare to Outperform from Underperform, with new targets of Rs 10,500 and Rs 1,450 according to reports. At 11:46 IST on NSE, Apollo is at Rs 9,109 (+4.25%), Max at Rs 1,071.10 (+2.93%) and Aster DM at Rs 762.10 (+3.08%), while Molbio Diagnostics is down 0.89% at Rs 1,512.80. The reported Macquarie note covers Apollo and Max only, so it says nothing about Aster or Molbio. On the September quarter, Apollo grew profit 33.5%, Max reported lower profit on a high base, Aster’s numbers jumped on a larger base and Molbio’s revenue fell 54.5%, so the four names carry very different risks.

Healthcare stocks today are rising on 20 November 2026 as Apollo Hospitals, Max Healthcare and Aster DM gain 3% to 4% on NSE, even though the broader market opened weak.

This article sets out the Macquarie upgrade, a side-by-side table of Apollo, Max, Aster and Molbio, the latest quarterly results and the risks. Figures marked as our arithmetic are recomputed from NSE prices at 11:46 IST.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Live Snapshot at 11:46 IST
  • What Macquarie Changed
  • How Other Brokerages Saw the Two Hospital Majors
  • Healthcare Stocks Today: Apollo, Max, Aster and Molbio Compared
  • Latest Quarter: September 2026 Against September 2025
  • Aster and Molbio: Why They Do Not Fit the Same Story
  • Risks Across the Sector
  • How to Weigh the Four Names and What to Track
  • Conclusion
  • Frequently Asked Questions
    • Why are hospital shares rising on 20 November 2026?
    • What are Macquarie’s new targets for Apollo Hospitals and Max Healthcare?
    • Which is better among Apollo Hospitals, Aster DM and Molbio Diagnostics?
    • Why did Molbio Diagnostics fall when hospital stocks rose?
    • How did Apollo Hospitals perform in the September 2026 quarter?
    • Is the Aster DM revenue jump real growth?
    • Are Apollo and Max a safe way to invest in hospitals?

Live Snapshot at 11:46 IST

Stock Price on NSE Change Previous close Day high
Apollo Hospitals Rs 9,109.00 +4.25% Rs 8,738.00 Rs 9,205.00
Max Healthcare Rs 1,071.10 +2.93% Rs 1,040.65 Rs 1,090.00
Aster DM Healthcare Rs 762.10 +3.08% Rs 739.30 Rs 764.00
Molbio Diagnostics Rs 1,512.80 -0.89% Rs 1,526.40 Rs 1,580.00

Molbio is the odd one out, since it is trading lower while the hospital operators rise. The headline groups the three names, but they are in different businesses: Apollo, Max and Aster run hospitals, while Molbio makes molecular diagnostic kits and equipment. Compare the latest quarter with the previous one when thinking about the sector’s listed names, and return to the filing if something looks odd.

The broader market opened weak and then recovered. The Nifty 50 is at 25,557.40 (+0.17%) and the Sensex at 83,187.56 (+0.20%) after the Sensex touched 82,403.27 early on, so the hospital stocks are moving on their own news. Business Standard reported that the BSE Hospitals index was up about 3% and had gained 20% in a month against 12.7% for the Sensex. Experienced investors usually wait for confirmation before acting on India’s hospital shares, and weigh it against your own time horizon.

What Macquarie Changed

Stock Earlier view New view Old and new target Gap to live price (our arithmetic)
Apollo Hospitals Underperform Outperform Rs 6,230 to Rs 10,500 +15.3%
Max Healthcare Underperform Outperform Rs 825 to Rs 1,450 +35.4%

Reports citing a CNBC story say Macquarie upgraded both stocks because earnings prospects are improving and valuations have become more attractive. The brokerage had held Underperform ratings on both in January, when it pointed to aggressive capacity additions across the sector. Liquidity and bid-ask spreads deserve a look when reading the sector’s listed names, because markets reprice quickly on new information.

The jump in Max Healthcare’s target from Rs 825 to Rs 1,450 is large by any measure, and the reports do not give the full reasoning, so the original note is worth reading. A target is one firm’s opinion with its own assumptions, and it is not a Univest view. Revisit your assumptions after each new filing when tracking the hospital chains, and compare at least two sources for the same number.

Aster DM and Molbio do not appear in the reports on the upgrade. Any link between the Macquarie note and their moves today would be an assumption. Sector peers give a useful yardstick when reading the hospital chains, while keeping an eye on the wider index.

How Other Brokerages Saw the Two Hospital Majors

Brokerage and date Stock Target Gap to live price (our arithmetic)
Jefferies, 1 October 2026 Apollo Hospitals Rs 10,350 +13.6%
Prabhudas Lilladher, 6 November 2026 Apollo Hospitals Rs 10,500 +15.3%
Jefferies, 1 October 2026 Max Healthcare Rs 1,260 +17.6%
ICICI Securities, 4 November 2026 Max Healthcare Rs 1,300 +21.4%

Targets from different houses sit close together for Apollo and further apart for Max, where Macquarie’s Rs 1,450 is the highest of the four. The views were set at different dates and prices, so the gaps shown here are recalculated against today’s quote and are not what each firm calculated at the time. Note the source and date of every figure when writing about the hospital stocks, and do not assume that a past pattern will repeat. A short list of questions helps when thinking about the sector’s listed names, then compare it with the sector average.

Brokerage targets change often and have missed in both directions. They are best used to understand an argument, such as bed expansion or margin gains, and not as a forecast. Treat any single headline as incomplete when reading the sector’s listed names, and see how the picture looks at the end of the week. Past patterns give context, not certainty, when reading about the hospital chains, and weigh it against your own time horizon.

Healthcare Stocks Today: Apollo, Max, Aster and Molbio Compared

Measure Apollo Hospitals Max Healthcare Aster DM Healthcare Molbio Diagnostics
Price on NSE Rs 9,109.00 Rs 1,071.10 Rs 762.10 Rs 1,512.80
Price to earnings (our arithmetic) 56.0 75.5 About 105, see note 123.1
Price to book (our arithmetic) 12.4 9.2 10.2 on FY26 book value 12.1
Return on equity 21.14% 12.18% Not compared 10.72%
Debt to equity 0.77 0.33 0.58 for FY26 0.27

The industry price to earnings figure is 63.67. Apollo is below it, Max is above it, and Molbio trades at about twice the sector level on trailing profit that has just fallen sharply. A high multiple is a statement about expected growth, and it leaves little room if that growth slows. Official disclosures should anchor any discussion about India’s hospital shares, especially around results and corporate announcements. Experienced investors usually wait for confirmation before acting on the healthcare rally, and look for confirmation across several data points.

For Aster, the multiple is the price divided by the last four quarters of diluted earnings per share added together, which is Rs 7.23 (our arithmetic). Aster’s share count and scale changed during the period, so treat that figure as a rough marker and compare it with the company’s own filings. Check the exchange filings before forming a view on the healthcare rally, because one session rarely tells the full story. Verify the time stamp on every quote you use while reading the hospital stocks, while treating third-party opinions as inputs only.

Apollo earns the highest return on equity of the group at 21.14%, but it also carries the most debt relative to equity among the hospital operators. Max has the strongest balance sheet by that measure. Time horizon decides how much weight to give to India’s hospital shares, because liquidity can thin out near the close.

Compare hospital and healthcare stocks with the Univest Screener

Latest Quarter: September 2026 Against September 2025

Company Revenue (Rs crore) Revenue change Net profit (Rs crore) Profit change
Apollo Hospitals 7,659.70 +22.7% 659.50 +33.5%
Max Healthcare 2,610.11 +20.4% 414.45 -15.6%
Aster DM Healthcare 2,880.73 +135.1% 322.38 +165.7%
Molbio Diagnostics 264.79 -54.5% 7.70 -92.8%

Apollo’s quarter is the cleanest of the four, with revenue, operating profit and net profit all growing at a fast pace. Operating profit before depreciation rose 26.2% to Rs 1,235.60 crore (our arithmetic). Reading the fine print is a good habit before settling on a view of the healthcare rally, especially around results and corporate announcements.

Max shows a mixed picture. Operating profit before depreciation rose 23.7% to Rs 752.39 crore, yet net profit fell 15.6%, and the year-earlier quarter had a higher profit base of Rs 491.30 crore. The filing explains the gap, so check it before reading the decline as a weakening of the core business. Experienced investors usually wait for confirmation before acting on the hospital stocks, because liquidity can thin out near the close.

Aster’s revenue more than doubled, which is far more than organic growth normally delivers, and points to a larger consolidated business after a restructuring. Compare it with the company’s disclosures and not with the old base. A calm second look at the numbers helps when reading the hospital stocks, because markets reprice quickly on new information.

Aster and Molbio: Why They Do Not Fit the Same Story

Aster DM is up 3.08% at Rs 762.10 and sits within the hospital group that is rising today. Its operating margin was 24.32% in the September 2026 quarter against 22.03% a year earlier, and it has no dividend recorded for the last five quarters in the data we reviewed. Total revenue for FY26 was Rs 4,768.82 crore with net profit of Rs 427.10 crore. Reading the fine print is a good habit before settling on a view of the hospital stocks, since small differences in timing can change the outcome. Small position sizes keep mistakes affordable when acting on the sector’s listed names, because liquidity can thin out near the close.

Molbio Diagnostics is down 0.89% at Rs 1,512.80 and is not a hospital operator. Revenue fell from Rs 581.36 crore to Rs 264.79 crore over the year to September 2026, and net profit fell from Rs 106.84 crore to Rs 7.70 crore. The company still trades at about 123 times trailing earnings, so the market price assumes a recovery that the latest quarter does not yet show. Policy and global cues can shift the picture quickly when tracking the hospital stocks, and weigh it against your own time horizon. Note the source and date of every figure when writing about the sector’s listed names, and check whether the news was already in the price.

The headline asks which is a better bet. The numbers point to differences in risk and not to a winner, because growth, valuation and balance sheet strength favour different names on different measures. Market direction on the day also colours any view on the sector’s listed names, and look for confirmation across several data points. Official disclosures should anchor any discussion about the hospital chains, and remember that targets and levels are not guarantees.

Risks Across the Sector

Risk What to watch
Regulation Kotak Neo reported a sell-off on 16 November over concerns about restrictions on healthcare, followed by a rebound of 2% to 6%
Capacity additions Macquarie’s January note warned that fast bed expansion could weigh on earnings
Valuation Apollo trades near 56 times and Max near 75 times trailing earnings, against an industry level of 63.67
Foreign holding Max’s foreign institutional holding fell to 40.52% in September 2026 from 45.39% in March 2026
After a strong run The hospital index gained 20% in a month, so profit booking can follow quickly

None of these risks removes the demand story for hospital services. They explain why hospital shares can fall several percent in a day even when business results are strong. Separate facts from opinion while reading the hospital chains, and separate what is reported from what is confirmed. Compare the latest quarter with the previous one when thinking about India’s hospital shares, and see how the picture looks at the end of the week.

Univest does not give buy or sell calls, and this article is general information. Size any position to your own risk limits. A fair review looks at both the positives and the risks of the healthcare rally, which keeps the discussion grounded in data.

How to Weigh the Four Names and What to Track

A fair comparison uses a few steps: growth in the latest quarter, the multiple paid for it, the strength of the balance sheet and how much of the rally rests on a single brokerage opinion. On those steps Apollo leads on growth and returns, Max has the lightest debt among the hospital operators, and Molbio’s latest quarter shows weakness on both growth and profit. Volume and delivery data add useful context when watching the hospital chains, and avoid chasing a move that has already happened. Check the exchange filings before forming a view on India’s hospital shares, while keeping an eye on the wider index.

The next data points are the full Macquarie note, the December quarter results due in February, any regulatory announcement on pricing and the Nifty 50 and sector index levels, which have been rising together. Volume on up days will show whether institutions are buying or only short-term traders. Keep a written note of the price level you are using while tracking India’s hospital shares, especially if the quote is more than a few minutes old. Volume and delivery data add useful context when watching the healthcare rally, as sentiment can turn within hours.

Anyone comparing these names should read each company’s own filings rather than a headline that pairs them. Compare the latest quarter with the previous one when thinking about the healthcare rally, while treating third-party opinions as inputs only. Note the source and date of every figure when writing about the hospital stocks, and compare at least two sources for the same number.

Download the Univest iOS App or Univest Android App to track Apollo, Max and Aster prices in one watchlist.

Conclusion

Apollo Hospitals, Max Healthcare and Aster DM rose 3% to 4% on 20 November after Macquarie upgraded the first two to Outperform with targets of Rs 10,500 and Rs 1,450, while Molbio Diagnostics slipped 0.89%. The upgrade explains the Apollo and Max moves, and it says nothing about Aster or Molbio. Market direction on the day also colours any view on the healthcare rally, and separate what is reported from what is confirmed. Scenario thinking is more useful than prediction when reading about the hospital stocks, especially around results and corporate announcements.

The four companies differ widely: Apollo grew profit 33.5%, Max’s profit fell on a high base, Aster’s results reflect a larger business and Molbio’s revenue and profit dropped sharply. Valuations are high across the group, so results and regulation will drive the next moves. Past patterns give context, not certainty, when reading about the hospital chains, and separate what is reported from what is confirmed. Small position sizes keep mistakes affordable when acting on India’s hospital shares, and scale any position to the risk you can absorb.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why are hospital shares rising on 20 November 2026?

Ans. Macquarie upgraded Apollo Hospitals and Max Healthcare to Outperform from Underperform on improving earnings prospects and more attractive valuations, according to reports. Apollo rose 4.25% to Rs 9,109 and Max 2.93% to Rs 1,071.10 at 11:46 IST, and Aster DM gained 3.08% in sympathy, though the reports do not link it to the note.

What are Macquarie’s new targets for Apollo Hospitals and Max Healthcare?

Ans. Reports put Macquarie’s target for Apollo Hospitals at Rs 10,500, up from Rs 6,230, and for Max Healthcare at Rs 1,450, up from Rs 825. At today’s prices that is a gap of about 15.3% for Apollo and 35.4% for Max (our arithmetic). A target is a brokerage opinion and not a forecast.

Which is better among Apollo Hospitals, Aster DM and Molbio Diagnostics?

Ans. Univest does not rank these for you. Apollo has the strongest growth and return on equity, Max has the lowest debt among the hospital operators, Aster’s results reflect a much larger business, and Molbio’s latest quarter showed falling revenue and profit. Weigh growth, valuation and risk against your own goals.

Why did Molbio Diagnostics fall when hospital stocks rose?

Ans. Molbio is a diagnostics company and not a hospital operator, and the Macquarie upgrade covered Apollo and Max. Its September 2026 quarter showed revenue down 54.5% and net profit down 92.8% from a year earlier, and it still trades at about 123 times trailing earnings, which leaves the stock sensitive to results.

How did Apollo Hospitals perform in the September 2026 quarter?

Ans. Apollo reported revenue of Rs 7,659.70 crore, up 22.7% from Rs 6,243.30 crore a year earlier, and net profit of Rs 659.50 crore, up 33.5%. Operating profit before depreciation rose 26.2% to Rs 1,235.60 crore (our arithmetic). These figures are from consolidated quarterly data and should be checked against the filing.

Is the Aster DM revenue jump real growth?

Ans. Aster’s September 2026 revenue of Rs 2,880.73 crore is 135.1% above the year-earlier Rs 1,225.46 crore, which is far more than hospital operators normally grow in a year. It points to a larger consolidated business after a restructuring, so compare the quarter with the company’s own disclosures and not with the old base.

Are Apollo and Max a safe way to invest in hospitals?

Ans. Univest does not give buy or sell calls, and no stock is risk-free. Apollo trades near 56 times and Max near 75 times trailing earnings, and both can fall quickly on regulatory news or profit booking after a rally. Read the filings, diversify and size any position to your risk limits.



Apollo Hospitals share price Aster DM Share Price BSE Hospitals Index Healthcare Stocks Today Hospital stocks Macquarie Upgrade Max Healthcare share price Molbio Diagnostics Share Price
Author: Harsh Piplani
I am Harsh Piplani, an Assistant Content Manager with over 5 years of experience in crafting impactful, result-driven content. I hold a B.Com (Hons) degree and have worked across diverse industries, including education, fintech, healthcare, jewellery, and more. I specialise in content strategy, SEO, and optimisation, ensuring that every piece I create is not just well-written but also well-ranked. I believe content should do more than fill space so as to drive traffic, build authority, and support business growth. I enjoy turning complex ideas into clear, engaging narratives, and, as I like to say, I know how to spin words like a web to influence, structured, strategic, and impossible to ignore. For me, great content sits at the intersection of creativity and performance.

Leave a Reply Cancel reply